PDFE-2304 not checked
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Approximately one mL dose applied onto a pre-specified scalp area twice daily for 16 weeks.”In the company’s words, NCT07011485 on ClinicalTrials.gov
- Tested for
- Alopecia, Androgenetic, Baldness, Androgenetic Alopecia (AGA)
- Main trialPhase 2
- “This study will evaluate the safety and efficacy of PDFE-2304 compared with Minoxidil 5% in men with androgenic alopecia (AGA).”In the company’s words, NCT07011485 on ClinicalTrials.gov
Other drugs for Alopecia, Androgenetic
- RitlecitinibPfizer · Phase 3
- VDPHL01Veradermics, Inc. · Phase 3
- OMA102EMS · Phase 3
- DA-001Applied Biology, Inc. · Phase 2/3
- DeuruxolitinibSun Pharma · Phase 3
- CKD-843Chong Kun Dang Pharmaceutical · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 14 Aug 2025 | A Safety and Efficacy Study of PDFE-2304 Topical Solution for the Treatment of Androgenic Alopecia. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026